Clinical outcome of metastatic uterine leiomyosarcoma and carcinosarcoma in a single institute

Yoshinaga, Mitsuhiro; Togami, Shinichi; Tsuji, Takahiro; Fukamachi, Nobuyuki; Kitajima, Masaki; Yanagi, Masakazu; Douchi, Tsutomu

doi:10.1111/j.1447-0756.2007.00662.x

Cited by 5 publications

(4 citation statements)

References 22 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most previous studies have focused on single sites of distant metastasis from EC, and most of the related reports describe single cases or small single‐center case series, with no large population‐level studies. Therefore, the aim of the present study was to evaluate the relationships between organ‐specific distant metastasis and overall survival in newly diagnosed cases of EC by using the Surveillance, Epidemiology, and End Results (SEER) database.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of distant metastatic sites in stage IV endometrial cancer: A SEER database study of 2948 women

Liu

Chi

Zhou

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To evaluate the prognosis of women with distant metastasis at the time of endometrial cancer (EC) diagnosis and identify prognostic factors according to metastatic site. Methods A retrospective cohort study of women diagnosed with EC according to the SEER database between 2010 and 2014. Univariate and multivariate Cox regression was used to identify variables associated with overall survival. Kaplan‐Meier curves were used to compare survival among different groups. Results Overall, 2948 women with stage IV EC were identified. The most common distant metastatic site was the lung. Having a distant metastatic site independently predicted overall survival. Using brain metastasis as a reference, overall survival was longer for liver (P=0.049), lung (P=0.005), and bone (P=0.019) metastasis. Relative to no distant metastasis, overall survival was shorter for women with one (P<0.001) or two or more (P<0.001) sites of distant metastasis. Overall survival was independently influenced by tumor grade, insurance status, and surgery among women with only lung metastasis. Conclusion The findings showed that the prognosis of women with stage IV EC differs by distant metastatic site, and identified several predictors of poor survival. They may help clinicians to better predict prognosis for newly diagnosed cases of EC with distant metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic value of distant metastatic sites in stage IV endometrial cancer: A SEER database study of 2948 women

Liu

Chi

Zhou

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Pulmonary or abdominal resection is consid-ered an acceptable treatment to improve survival. 6,7 Pancreatic metastases are very rare, and to our knowledge, this is the third case reported in the literature.…”

mentioning

confidence: 72%

Image of the Month—Diagnosis

2010

Arch Surg

View full text Add to dashboard Cite

“…SCS for patients who have pulmonary recurrent disease has been reported to lead to improved survival, particularly in those with unilateral disease, a smaller number of resected metastases (<3), a smaller tumor (<3 cm) and a longer DFI (<6, or 12 months) (8)(9)(10). However, studies on SCS for extra-pulmonary recurrences of uterine sarcomas are limited, and have only small sample sizes (4,11,(14)(15)(16)(17). Leitao et al (14) reported that optimal surgical resection may improve the survival of patients with either pulmonary or extra-pulmonary metastases, after retrospectively surveying 41 patients with recurrent LMS (including 28 patients who had non-thoracic recurrences).…”

Section: Discussionmentioning

confidence: 99%

“…Leitao et al (14) reported that optimal surgical resection may improve the survival of patients with either pulmonary or extra-pulmonary metastases, after retrospectively surveying 41 patients with recurrent LMS (including 28 patients who had non-thoracic recurrences). Yoshinaga et al (17) concluded that patient survival was Table II. The site of recurrence in patients with or without SCS.…”

Section: Discussionmentioning

confidence: 99%

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

et al. 2018

View full text Add to dashboard Cite

Abstract. Uterine sarcomas are some of the most malignant and aggressive tumor types among the gynecologic malignancies, and they are associated with a high rate of recurrence and a poor prognosis. Due to their rarity and diversity, the optimal treatment for recurrent uterine sarcomas has not yet been elucidated. The aim of the present study was to investigate the potential of secondary cytoreductive surgery (SCS) for patients with recurrent uterine sarcomas. A total of 18 patients with recurrent uterine sarcomas were retrospectively identified at the

show abstract

Clinical outcome of metastatic uterine leiomyosarcoma and carcinosarcoma in a single institute

Abstract: Resection of lung and abdominal metastases in uterine LMS and CS is beneficial to improve patient survival.

Cited by 5 publications

References 22 publications

Prognostic value of distant metastatic sites in stage IV endometrial cancer: A SEER database study of 2948 women

Prognostic value of distant metastatic sites in stage IV endometrial cancer: A SEER database study of 2948 women

Image of the Month—Diagnosis

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

Contact Info

Product

Resources

About